Introducing BRUKINSA™ (zanubrutinib)—the new BTK inhibitor
- Amanda Bridges
- November 18, 2019
- Drugs
- No Comments
FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumor shrinkage For Immediate Release: November 14, 2019 Today, the U.S. Food and Drug Administration granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients with mantle cell lymphoma…